Workflow
温敏相变技术
icon
Search documents
“她经济”蓬勃发展,“悦秘境”抑菌液打造医研企协同创新模式
Huan Qiu Wang Zi Xun· 2025-09-12 09:44
Core Insights - The intimate care market is undergoing a significant transformation from traditional maintenance to technology-driven precision care, driven by the growth of the "she economy" and the increasing purchasing power of the post-90s and post-00s generations [1] - The market size has rapidly increased from 13.04 billion yuan in 2016 to 34.65 billion yuan in 2023, with expectations to exceed 45 billion yuan by 2026, indicating strong growth potential [1] Company Overview - Beijing Saiweisen International Biotechnology Co., Ltd. has launched the brand "Yue Mijing," which redefines women's intimate care standards through a collaborative innovation model and patented technologies [1] - The company emphasizes supply chain management and quality control, sourcing key raw materials from biotechnology firms with proprietary technologies [1] Product Innovation - The "Yue Mijing" antibacterial liquid addresses industry pain points related to absorption efficiency and safety residues, with traditional products facing challenges in effective ingredient coverage and potential irritation risks [4][5] - The product utilizes "temperature-sensitive phase change technology," allowing it to remain liquid at room temperature and solidify upon contact with body temperature, enhancing its effectiveness [4][5] Clinical Validation - Clinical tests indicate that the antibacterial liquid can effectively inhibit bacteria such as Staphylococcus aureus and Escherichia coli while being naturally expelled from the body after use [5] - The development team includes experts from top-tier hospitals, ensuring a strong clinical foundation for the product [5] Patent and Ingredient Innovation - The product is supported by a robust patent matrix covering core ingredients, extraction processes, and formulation technologies, including the proprietary compound "Runbai Fu" derived from traditional Chinese medicine [6][7] - The extraction technology enhances the safety and stability of the ingredients while maintaining the advantages of traditional herbal medicine [8] Market Trends - The demand for intimate care products among women has evolved from basic hygiene to health management and quality of life enhancement, reflecting changing consumer preferences [9][10] - The product has passed rigorous skin irritation tests and avoids traditional chemical preservatives, offering a safer alternative for consumers [9][10]
“悦秘境”抑菌液打造医研企协同创新模式
Jing Ji Wang· 2025-09-12 09:41
Core Insights - Beijing Saiweisen International Biotechnology Co., Ltd. launched the brand "Yue Mijing," redefining women's intimate care standards through innovative solutions backed by patented technologies [1][2] - The company emphasizes supply chain management and quality control, sourcing key raw materials from biotech firms with proprietary technologies [1] - The growth of the "she economy" and the increasing health awareness among women, particularly those born in the 90s and 00s, are driving the expansion of the female consumer market [1] Product Innovation - The "Yue Mijing" antibacterial solution addresses industry pain points by utilizing "temperature-sensitive phase change technology," allowing the product to transition from liquid to gel at body temperature [2] - Clinical tests indicate that the product effectively inhibits bacteria such as Staphylococcus aureus and E. coli while being naturally expelled from the body, a feature lacking in existing products [2] - The product's formulation includes a proprietary blend of herbal extracts, enhancing its antioxidant, anti-inflammatory, and antibacterial properties [2] Market Context - The intimate care product market shows a significant demand, with intimate care liquids accounting for 48.8% of the market share, yet traditional products face challenges in absorption efficiency and safety [1] - Analysts highlight that many existing products suffer from a lack of research and development focus, contrasting with Saiweisen's commitment to innovation and collaboration with clinical experts [2]